MSRV GNbAC1 from GeNeuro

[1eye]

From their newsletter: (This is about therapy for MSRV or MS retrovirus.)

GNbAC1 has successfully completed Phase I in healthy volunteers showing that GNbAC1 is very well tolerated. GNbAC1 has also successfully completed Phase IIa last year, demonstrating an optimal safety profile and encouraging signs of efficacy on a first mall cohort of MS patients.

Information about the clinical trials are posted on http://www.clinicaltrials.gov,
identifiers NCT01639300 & NCT01699555.

A multicentric Phase IIb study in MS to test GNbAC1 is in preparation. Recruitment is expected to begin by the end 2015

GeNeuro launched two years ago longitudinal epidemiological studies to follow the evolution of the HERV proteins in populations of MS patients and healthy controls. The recruitment and following of participants are now closed. Analysis of samples will be performed within following months.

Information are posted on http://www.clinicaltrials.gov, identifiers NCT01804660
& NCT01804647.

Regulatory toxicology, Phase I Phase IIa CMC Preclinical Development Clinical Development GNbAC1 Fully funded through Phase III Multiple Sclerosis Proof-of-concept Phase IIa trial in preparation GNbAC1 Inflammatory schizophrenia CHMP (Committee for Medicinal Products for Human Use) green light for proof-of-concept trial GNbAC1

GeNeuro will present its scientific developments at the
following meetings:
International Workshop on Human Endogenous Retroviruses
and Diseases, 26-27 May 2015, Lyon – France
GeNeuro will receive the Innovation Trophee of the CCIFS
(Chambers of commerce and industry France-Switzerland), 20
February 2015, Montreux - Switzerland

[CureOrBust]

Didn't want to start a new thread, but found this thread and:

http://www.thisisms.com/forum/drug-pipe ... ml#p232120
http://www.thisisms.com/forum/general-d ... 23305.html

Did some google searching to see where it was all at, and found:

SESSION 5:
AUTOIMMUNITY/ANTI-INFLAMMATORY
Final Conference Programme | Thursday 29th October 2015
10.20-10.40
‘Clinical positioning of the anti-HERV mAB GNbAC1 for the treatment of multiple sclerosis’
François Curtin (GeNeuro SA, Plan-les-Ouates, Geneva, Switzerland)

http://www.meetingsmanagement.co.uk/ind ... Itemid=568
So any idea as to what was actually presented?

There is also a video on their web site
http://www.geneuro.com/en/news.php

I haven't myself, but maybe someone could contact them directly to see if we could get anymore information

I have also search the clinical trials website, and only found links to their completed safety trials; ie not efficacy.